Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma. Okada T, Fushimi C, Matsuki T, Okamoto I, et al. Anticancer Res 2022;42:1607-1613.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Okada T, Fushimi C, Matsuki T, Okamoto I, et al. Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma. Anticancer Res 2022;42:1607-1613.
PMID: 35220258